BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 30999964)

  • 1. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.
    Bol KF; Schreibelt G; Rabold K; Wculek SK; Schwarze JK; Dzionek A; Teijeira A; Kandalaft LE; Romero P; Coukos G; Neyns B; Sancho D; Melero I; de Vries IJM
    J Immunother Cancer; 2019 Apr; 7(1):109. PubMed ID: 30999964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.
    Tel J; Schreibelt G; Sittig SP; Mathan TS; Buschow SI; Cruz LJ; Lambeck AJ; Figdor CG; de Vries IJ
    Blood; 2013 Jan; 121(3):459-67. PubMed ID: 23212525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy.
    Schreibelt G; Tel J; Sliepen KH; Benitez-Ribas D; Figdor CG; Adema GJ; de Vries IJ
    Cancer Immunol Immunother; 2010 Oct; 59(10):1573-82. PubMed ID: 20204387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-small Cell Lung Cancer Cells Modulate the Development of Human CD1c
    Lu Y; Xu W; Gu Y; Chang X; Wei G; Rong Z; Qin L; Chen X; Zhou F
    Front Immunol; 2019; 10():2829. PubMed ID: 31921114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential approaches for more successful dendritic cell-based immunotherapy.
    Chiang CL; Balint K; Coukos G; Kandalaft LE
    Expert Opin Biol Ther; 2015 Apr; 15(4):569-82. PubMed ID: 25553913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute aerobic exercise induces a preferential mobilisation of plasmacytoid dendritic cells into the peripheral blood in man.
    Brown FF; Campbell JP; Wadley AJ; Fisher JP; Aldred S; Turner JE
    Physiol Behav; 2018 Oct; 194():191-198. PubMed ID: 29763678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy.
    Bakdash G; Schreurs I; Schreibelt G; Tel J
    Expert Rev Clin Immunol; 2014 Jul; 10(7):915-26. PubMed ID: 24758519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased tubulointerstitial recruitment of human CD141(hi) CLEC9A(+) and CD1c(+) myeloid dendritic cell subsets in renal fibrosis and chronic kidney disease.
    Kassianos AJ; Wang X; Sampangi S; Muczynski K; Healy H; Wilkinson R
    Am J Physiol Renal Physiol; 2013 Nov; 305(10):F1391-401. PubMed ID: 24049150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell vaccination in melanoma patients: From promising results to future perspectives.
    Boudewijns S; Bloemendal M; Gerritsen WR; de Vries IJ; Schreibelt G
    Hum Vaccin Immunother; 2016 Oct; 12(10):2523-2528. PubMed ID: 27322496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.
    Jongbloed SL; Kassianos AJ; McDonald KJ; Clark GJ; Ju X; Angel CE; Chen CJ; Dunbar PR; Wadley RB; Jeet V; Vulink AJ; Hart DN; Radford KJ
    J Exp Med; 2010 Jun; 207(6):1247-60. PubMed ID: 20479116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmacytoid Dendritic Cells and Cancer Immunotherapy.
    Fu C; Zhou L; Mi QS; Jiang A
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets.
    Wimmers F; Schreibelt G; Sköld AE; Figdor CG; De Vries IJ
    Front Immunol; 2014; 5():165. PubMed ID: 24782868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid Arthritis.
    Cooles FAH; Anderson AE; Skelton A; Pratt AG; Kurowska-Stolarska MS; McInnes I; Hilkens CMU; Isaacs JD
    Front Immunol; 2018; 9():755. PubMed ID: 29867920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report:
    Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
    Front Immunol; 2021; 12():752563. PubMed ID: 35003064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Human Blood Dendritic Cells for Cancer Immunotherapy-Tailoring the Immune Response by Dendritic Cell Maturation.
    Sittig SP; de Vries IJM; Schreibelt G
    Biomedicines; 2015 Dec; 3(4):282-303. PubMed ID: 28536413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients.
    Nava S; Lisini D; Pogliani S; Dossena M; Bersano A; Pellegatta S; Parati E; Finocchiaro G; Frigerio S
    Stem Cells Transl Med; 2015 Oct; 4(10):1164-72. PubMed ID: 26273063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets.
    Sittig SP; Bakdash G; Weiden J; Sköld AE; Tel J; Figdor CG; de Vries IJ; Schreibelt G
    Mediators Inflamm; 2016; 2016():3605643. PubMed ID: 27057096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular immunotherapy with dendritic cells in cancer: current status.
    Nencioni A; Brossart P
    Stem Cells; 2004; 22(4):501-13. PubMed ID: 15277696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumoricidal activity of human dendritic cells.
    Tel J; Anguille S; Waterborg CE; Smits EL; Figdor CG; de Vries IJ
    Trends Immunol; 2014 Jan; 35(1):38-46. PubMed ID: 24262387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CLEC10A Is a Specific Marker for Human CD1c
    Heger L; Balk S; Lühr JJ; Heidkamp GF; Lehmann CHK; Hatscher L; Purbojo A; Hartmann A; Garcia-Martin F; Nishimura SI; Cesnjevar R; Nimmerjahn F; Dudziak D
    Front Immunol; 2018; 9():744. PubMed ID: 29755453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.